Defining the condensate landscape of fusion oncoproteins
-
Published:2023-09-28
Issue:1
Volume:14
Page:
-
ISSN:2041-1723
-
Container-title:Nature Communications
-
language:en
-
Short-container-title:Nat Commun
Author:
Tripathi Swarnendu, Shirnekhi Hazheen K.ORCID, Gorman Scott D.ORCID, Chandra Bappaditya, Baggett David W., Park Cheon-Gil, Somjee RamizORCID, Lang BenjaminORCID, Hosseini Seyed Mohammad Hadi, Pioso Brittany J.ORCID, Li YongshengORCID, Iacobucci IlariaORCID, Gao Qingsong, Edmonson Michael N.ORCID, Rice Stephen V., Zhou Xin, Bollinger John, Mitrea Diana M., White Michael R., McGrail Daniel J.ORCID, Jarosz Daniel F.ORCID, Yi S. StephenORCID, Babu M. MadanORCID, Mullighan Charles G.ORCID, Zhang JinghuiORCID, Sahni NidhiORCID, Kriwacki Richard W.ORCID
Abstract
AbstractFusion oncoproteins (FOs) arise from chromosomal translocations in ~17% of cancers and are often oncogenic drivers. Although some FOs can promote oncogenesis by undergoing liquid-liquid phase separation (LLPS) to form aberrant biomolecular condensates, the generality of this phenomenon is unknown. We explored this question by testing 166 FOs in HeLa cells and found that 58% formed condensates. The condensate-forming FOs displayed physicochemical features distinct from those of condensate-negative FOs and segregated into distinct feature-based groups that aligned with their sub-cellular localization and biological function. Using Machine Learning, we developed a predictor of FO condensation behavior, and discovered that 67% of ~3000 additional FOs likely form condensates, with 35% of those predicted to function by altering gene expression. 47% of the predicted condensate-negative FOs were associated with cell signaling functions, suggesting a functional dichotomy between condensate-positive and -negative FOs. Our Datasets and reagents are rich resources to interrogate FO condensation in the future.
Funder
U.S. Department of Health & Human Services | NIH | National Cancer Institute Susan G. Komen Cancer Prevention and Research Institute of Texas
Publisher
Springer Science and Business Media LLC
Subject
General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry,Multidisciplinary
Reference105 articles.
1. Gao, Q. S. et al. Driver fusions and their implications in the development and treatment of human cancers. Cell Rep. 23, 227–238.e223 (2018). 2. Brien, G. L., Stegmaier, K. & Armstrong, S. A. Targeting chromatin complexes in fusion protein-driven malignancies. Nat. Rev. Cancer 19, 255–269 (2019). 3. Hu, X. et al. TumorFusions: an integrative resource for cancer-associated transcript fusions. Nucleic Acids Res. 46, D1144–D1149 (2018). 4. Gu, Z. et al. PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. Nat. Genet. 51, 296–307 (2019). 5. Stransky, N., Cerami, E., Schalm, S., Kim, J. L. & Lengauer, C. The landscape of kinase fusions in cancer. Nat. Commun. 5, 4846 (2014).
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|